Amicus Therapeutics to Announce First Quarter 2012 Financial Results on May 10, 2012
CRANBURY, N.J., May 4, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Thursday, May 10, 2012 at 5 p.m. ET to discuss financial results for the first quarter ended March 31, 2012.
The call with be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team.
Interested participants and investors may access the conference call at 5 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.
A telephonic replay of the call will be available for seven days beginning at 8 p.m. ET on May 10, 2012. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 78252460.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program migalastat HCl is in Phase 3 for the treatment of Fabry disease.
CONTACT: Investors/Media Sara Pellegrino firstname.lastname@example.org (609) 662-5044Source: Amicus Therapeutics 2012 GlobeNewswire, Inc.